US20150174254A1 - Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent - Google Patents

Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent Download PDF

Info

Publication number
US20150174254A1
US20150174254A1 US14/138,338 US201314138338A US2015174254A1 US 20150174254 A1 US20150174254 A1 US 20150174254A1 US 201314138338 A US201314138338 A US 201314138338A US 2015174254 A1 US2015174254 A1 US 2015174254A1
Authority
US
United States
Prior art keywords
composition
amount
weight
alcohol
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/138,338
Other languages
English (en)
Inventor
Ying Sun
Anna Gosiewska
Dennis Jamiolkowski
Jeffrey M. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US14/138,338 priority Critical patent/US20150174254A1/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOSIEWSKA, ANNA, SUN, YING, JAMIOLKOWSKI, DENNIS D.
Priority to JP2016542152A priority patent/JP2017500356A/ja
Priority to CN201480070704.4A priority patent/CN105848640B/zh
Priority to RU2016130098A priority patent/RU2016130098A/ru
Priority to KR1020167019808A priority patent/KR102378645B1/ko
Priority to BR112016014612-3A priority patent/BR112016014612B1/pt
Priority to PCT/US2014/070574 priority patent/WO2015100069A1/en
Priority to EP14827331.1A priority patent/EP3086775B1/en
Priority to CA2933864A priority patent/CA2933864C/en
Priority to SG11201605128XA priority patent/SG11201605128XA/en
Priority to ES14827331T priority patent/ES2720271T3/es
Priority to AU2014370226A priority patent/AU2014370226B2/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. CORRECTIVE ASSIGNMENT TO ADD AN OMITTED ASSIGNOR PREVIOUSLY RECORDED AT REEL: 033332 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: GOSIEWSKA, ANNA, SUN, YING, WU, JEFFREY M., JAMIOLKOWSKI, DENNIS D.
Publication of US20150174254A1 publication Critical patent/US20150174254A1/en
Assigned to JOHNSON & JOHNSON CONSUMER INC. reassignment JOHNSON & JOHNSON CONSUMER INC. MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: JOHNSON & JOHNSON CONSUMER INC., MCNEIL-PPC, INC.
Priority to US15/346,113 priority patent/US9782485B2/en
Priority to US15/353,848 priority patent/US20170065718A1/en
Priority to US15/696,662 priority patent/US10022448B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/85—Polyesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Definitions

  • safe and effective amount means an amount sufficient to provide a desired benefit at a desired level, but low enough to avoid serious undesirable side effects.
  • the safe and effective amount of the ingredient or composition will vary with the area being treated, the age of the end user, the duration and nature of the treatment, the specific ingredient or composition employed, the particular carrier utilized, and like factors.
  • the composition further contains a safe and effective amount of a benefit agent, for example, from about 0.001% to about 20%, or from about 0.01% to about 10%, or from about 1% to about 5% by weight of the composition of the benefit agent.
  • a benefit agent for example, from about 0.001% to about 20%, or from about 0.01% to about 10%, or from about 1% to about 5% by weight of the composition of the benefit agent.
  • the composition is incorporated into wound dressings or bandages to provide healing enhancement or scar prevention.
  • Wounds or lesions that may be treated include, but are not limited to acute wounds as well as chronic wounds including diabetic ulcer, venus ulcer, and pressure sores.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US14/138,338 2013-12-23 2013-12-23 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent Abandoned US20150174254A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US14/138,338 US20150174254A1 (en) 2013-12-23 2013-12-23 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
AU2014370226A AU2014370226B2 (en) 2013-12-23 2014-12-16 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
CA2933864A CA2933864C (en) 2013-12-23 2014-12-16 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
ES14827331T ES2720271T3 (es) 2013-12-23 2014-12-16 Composiciones de gel tópico que contienen un polímero de policaprolactona y métodos para mejorar la aplicación tópica de un agente beneficioso
RU2016130098A RU2016130098A (ru) 2013-12-23 2014-12-16 Композиции в виде геля для местного применения, включающие полимер поликапролактон, и способы повышения эффективности местного применения полезного средства
KR1020167019808A KR102378645B1 (ko) 2013-12-23 2014-12-16 폴리카프로락톤 중합체를 포함하는 국소 겔 조성물 및 효과제의 국소 적용을 향상시키기 위한 방법
BR112016014612-3A BR112016014612B1 (pt) 2013-12-23 2014-12-16 Composições tópicas em gel incluindo polímero de policaprolactona e métodos para aprimorar a aplicação tópica de um agente de benefício
PCT/US2014/070574 WO2015100069A1 (en) 2013-12-23 2014-12-16 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
EP14827331.1A EP3086775B1 (en) 2013-12-23 2014-12-16 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
JP2016542152A JP2017500356A (ja) 2013-12-23 2014-12-16 ポリカプロラクトンポリマーを含む局所用ゲル組成物、及び有益剤の局所適用を増強するための方法
SG11201605128XA SG11201605128XA (en) 2013-12-23 2014-12-16 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
CN201480070704.4A CN105848640B (zh) 2013-12-23 2014-12-16 包含聚己内酯聚合物的局部用凝胶组合物以及用于增强有益剂的局部施用的方法
US15/346,113 US9782485B2 (en) 2013-12-23 2016-11-08 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US15/353,848 US20170065718A1 (en) 2013-12-23 2016-11-17 Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
US15/696,662 US10022448B2 (en) 2013-12-23 2017-09-06 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/138,338 US20150174254A1 (en) 2013-12-23 2013-12-23 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/346,113 Division US9782485B2 (en) 2013-12-23 2016-11-08 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US15/353,848 Division US20170065718A1 (en) 2013-12-23 2016-11-17 Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent

Publications (1)

Publication Number Publication Date
US20150174254A1 true US20150174254A1 (en) 2015-06-25

Family

ID=52347424

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/138,338 Abandoned US20150174254A1 (en) 2013-12-23 2013-12-23 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US15/346,113 Active US9782485B2 (en) 2013-12-23 2016-11-08 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US15/353,848 Abandoned US20170065718A1 (en) 2013-12-23 2016-11-17 Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
US15/696,662 Active US10022448B2 (en) 2013-12-23 2017-09-06 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/346,113 Active US9782485B2 (en) 2013-12-23 2016-11-08 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US15/353,848 Abandoned US20170065718A1 (en) 2013-12-23 2016-11-17 Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
US15/696,662 Active US10022448B2 (en) 2013-12-23 2017-09-06 Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

Country Status (11)

Country Link
US (4) US20150174254A1 (ja)
EP (1) EP3086775B1 (ja)
JP (1) JP2017500356A (ja)
KR (1) KR102378645B1 (ja)
CN (1) CN105848640B (ja)
AU (1) AU2014370226B2 (ja)
CA (1) CA2933864C (ja)
ES (1) ES2720271T3 (ja)
RU (1) RU2016130098A (ja)
SG (1) SG11201605128XA (ja)
WO (1) WO2015100069A1 (ja)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9833748B2 (en) 2010-08-25 2017-12-05 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9870895B2 (en) 2014-01-31 2018-01-16 Lockheed Martin Corporation Methods for perforating two-dimensional materials using a broad ion field
US10005038B2 (en) 2014-09-02 2018-06-26 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
CN108210975A (zh) * 2018-02-06 2018-06-29 青岛海洋生物医药研究院 用于治疗痤疮的胶原敷料
US10017852B2 (en) 2016-04-14 2018-07-10 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
US10022448B2 (en) 2013-12-23 2018-07-17 Johnson & Johnson Consumer Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US10201784B2 (en) 2013-03-12 2019-02-12 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US10203295B2 (en) 2016-04-14 2019-02-12 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
US10213746B2 (en) 2016-04-14 2019-02-26 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10471199B2 (en) 2013-06-21 2019-11-12 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
US10500546B2 (en) 2014-01-31 2019-12-10 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10696554B2 (en) 2015-08-06 2020-06-30 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
KR102212787B1 (ko) * 2020-10-15 2021-02-08 (주)제이에이치사이언스 미백 기능의 필링제 조성물
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20070092574A1 (en) * 2003-07-23 2007-04-26 Pr Pharmaceuticals, Inc. Controlled released compositions
US20140135349A1 (en) * 2012-11-11 2014-05-15 Symrise Ag Aqueous Compositions
US20150216986A1 (en) * 2012-08-31 2015-08-06 Biolab Sanus Farmaceutia Ltda. Finasteride and minoxidil polymeric nonoparticle, its process of preparation, aqueous suspension containing the same, pharmaceutical composition, and its use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1075872A (zh) * 1993-01-01 1993-09-08 四川绵竹制药厂 治疗脱发症的外用药物
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
AU2001244730B2 (en) * 2000-04-07 2004-08-19 Taisho Pharmaceutical Co., Ltd. Hair growth stimulant compositions with sustained action
US7368125B2 (en) * 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
KR20040062379A (ko) * 2002-12-31 2004-07-07 주식회사 태평양 자기회합성을 갖는 양친성 고분자를 사용하여 난용성물질을 포집시켜 제조한 나노입자 및 이를 함유하는 피부외용제 조성물
JP4939936B2 (ja) * 2003-06-27 2012-05-30 株式會社アモーレパシフィック 生理活性成分を含有する自己集合性高分子ナノ粒子の製造方法、及び得られた自己集合性高分子ナノ粒子を含有する外用剤組成物
WO2005000258A1 (en) 2003-06-27 2005-01-06 Amorepacific Corporation Self-assembled polymeric nanoparticles containing physiologically active ingredients and external application containing the nanoparticles
US20050163811A1 (en) * 2004-01-23 2005-07-28 Richard Lee Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20060067958A1 (en) * 2004-09-24 2006-03-30 Unilab Pharmatech, Ltd. Pharmaceutical topical gel compositions
US8147815B2 (en) * 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
EP2386322B1 (de) * 2006-07-03 2017-12-27 Hemoteq AG Herstellung, Verfahren und Verwendung von wirkstofffreisetzenden Medizinprodukten zur permanenten Offenhaltung von Blutgefässen
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EA200970348A1 (ru) * 2006-10-05 2009-10-30 Панацея Биотек Лтд. Новые инъецируемые депо-композиции и способ получения таких композиций
CN101240149A (zh) * 2007-02-07 2008-08-13 天津大学 含有羟基酸低聚物的自促透压敏胶及其应用
FR2912917B1 (fr) * 2007-02-26 2012-05-18 Oreal Milieu conditionne et ses utilisations
CN100577168C (zh) * 2007-03-21 2010-01-06 遵义医学院附属医院 治疗脱发的乳膏剂及其制备方法
CA2823407C (en) * 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
WO2012040342A2 (en) * 2010-09-21 2012-03-29 Conrex Pharmaceutical Corporation Restoration of hair
WO2012160125A1 (en) * 2011-05-26 2012-11-29 Novartis Ag Compositions for percutaneous administration of physiologically active agents
US9522189B2 (en) * 2013-12-20 2016-12-20 Johnson & Johnson Consumer Inc. Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
US20150174254A1 (en) 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20070092574A1 (en) * 2003-07-23 2007-04-26 Pr Pharmaceuticals, Inc. Controlled released compositions
US20150216986A1 (en) * 2012-08-31 2015-08-06 Biolab Sanus Farmaceutia Ltda. Finasteride and minoxidil polymeric nonoparticle, its process of preparation, aqueous suspension containing the same, pharmaceutical composition, and its use
US20140135349A1 (en) * 2012-11-11 2014-05-15 Symrise Ag Aqueous Compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shim et al., "Transdermal delivery of minoxidil with block copolymer nanoparticles," Journal of Controlled Release 97 (2004) 477-484. *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833748B2 (en) 2010-08-25 2017-12-05 Lockheed Martin Corporation Perforated graphene deionization or desalination
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10201784B2 (en) 2013-03-12 2019-02-12 Lockheed Martin Corporation Method for forming perforated graphene with uniform aperture size
US10471199B2 (en) 2013-06-21 2019-11-12 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
US10022448B2 (en) 2013-12-23 2018-07-17 Johnson & Johnson Consumer Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9870895B2 (en) 2014-01-31 2018-01-16 Lockheed Martin Corporation Methods for perforating two-dimensional materials using a broad ion field
US10500546B2 (en) 2014-01-31 2019-12-10 Lockheed Martin Corporation Processes for forming composite structures with a two-dimensional material using a porous, non-sacrificial supporting layer
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US10005038B2 (en) 2014-09-02 2018-06-26 Lockheed Martin Corporation Hemodialysis and hemofiltration membranes based upon a two-dimensional membrane material and methods employing same
US10418143B2 (en) 2015-08-05 2019-09-17 Lockheed Martin Corporation Perforatable sheets of graphene-based material
US10696554B2 (en) 2015-08-06 2020-06-30 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
US10213746B2 (en) 2016-04-14 2019-02-26 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10203295B2 (en) 2016-04-14 2019-02-12 Lockheed Martin Corporation Methods for in situ monitoring and control of defect formation or healing
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US10017852B2 (en) 2016-04-14 2018-07-10 Lockheed Martin Corporation Method for treating graphene sheets for large-scale transfer using free-float method
US10981120B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Selective interfacial mitigation of graphene defects
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
CN108210975A (zh) * 2018-02-06 2018-06-29 青岛海洋生物医药研究院 用于治疗痤疮的胶原敷料
KR102212787B1 (ko) * 2020-10-15 2021-02-08 (주)제이에이치사이언스 미백 기능의 필링제 조성물

Also Published As

Publication number Publication date
BR112016014612A8 (pt) 2022-08-09
CA2933864A1 (en) 2015-07-02
US20170065718A1 (en) 2017-03-09
JP2017500356A (ja) 2017-01-05
US20170049681A1 (en) 2017-02-23
WO2015100069A1 (en) 2015-07-02
KR20160103041A (ko) 2016-08-31
EP3086775B1 (en) 2019-03-06
CA2933864C (en) 2021-11-02
CN105848640B (zh) 2019-03-29
AU2014370226A1 (en) 2016-06-30
SG11201605128XA (en) 2016-07-28
EP3086775A1 (en) 2016-11-02
AU2014370226B2 (en) 2020-02-27
CN105848640A (zh) 2016-08-10
US9782485B2 (en) 2017-10-10
KR102378645B1 (ko) 2022-03-28
BR112016014612A2 (ja) 2017-08-08
RU2016130098A (ru) 2018-01-30
US20170360941A1 (en) 2017-12-21
US10022448B2 (en) 2018-07-17
RU2016130098A3 (ja) 2018-07-17
ES2720271T3 (es) 2019-07-19

Similar Documents

Publication Publication Date Title
US10022448B2 (en) Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US9522189B2 (en) Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent
US9474699B2 (en) Compostions and methods for enhancing the topical application of a basic benefit agent
US6544401B1 (en) Biomimetic water solutions and compositions, their use as and in health and beauty care products and the methods to prepare them
US9468606B2 (en) Compostions and methods for enhancing the topical application of an acidic benefit agent
DE60122312T2 (de) Membranverabreichungssystem für wirkstoffe
US20170080257A1 (en) Devices and methods for enhancing the topical application of a benefit agent
WO2015195304A1 (en) Compositions and methods for enhancing the topical application of a benefit agent including powder to liquid particles and a second powder
US20110236503A1 (en) Topical Skincare Composition
EP2692337A1 (en) Film-shaped externally used drug composition
BR112016014612B1 (pt) Composições tópicas em gel incluindo polímero de policaprolactona e métodos para aprimorar a aplicação tópica de um agente de benefício

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUN, YING;GOSIEWSKA, ANNA;JAMIOLKOWSKI, DENNIS D.;SIGNING DATES FROM 20140226 TO 20140612;REEL/FRAME:033332/0245

AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: CORRECTIVE ASSIGNMENT TO ADD AN OMITTED ASSIGNOR PREVIOUSLY RECORDED AT REEL: 033332 FRAME: 0245. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:SUN, YING;GOSIEWSKA, ANNA;JAMIOLKOWSKI, DENNIS D.;AND OTHERS;SIGNING DATES FROM 20140226 TO 20140612;REEL/FRAME:035570/0792

AS Assignment

Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:MCNEIL-PPC, INC.;JOHNSON & JOHNSON CONSUMER INC.;REEL/FRAME:036042/0443

Effective date: 20150623

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION